摘要
目的 以药物利用评价(DUE)为基础,建立基于属性层次模型(AHM)结合加权优劣解距离(TOPSIS)法的替吉奥胶囊用药合理性评价标准,并评价替吉奥胶囊的用药合理性。方法 2023年1月,根据药品说明书、相关指南和文献等制定替吉奥胶囊用药合理性评价标准。分别抽取2022年1至12月(干预前)和2023年1至12月(干预后)使用替吉奥胶囊的病例各120例作为对照组和研究组。根据建立的替吉奥胶囊用药合理性评价标准分析对照组替吉奥胶囊用药不合理原因,并予针对性的改进措施。比较2组替吉奥胶囊的用药合理性。结果 对照组120例病例中Ci最高为100%,最低为36.6%,Ci≥80%的病例有47例(占39.17%),60%≤Ci<80%的病例有40例(占33.33%),Ci<60%的病例有33例(占27.50%)。研究组120例病例中Ci最高为100%,最低为43.6%,Ci≥80%的病例有81例(占67.50%),60%≤Ci<80%的病例有16例(占13.33%),Ci<60%的病例有23例(占19.17%);与对照组比较,研究组Ci≥80%的病例占比显著提高(P<0.05);在用法用量、适应证、疗程、不良反应监测与处理方面,研究组替吉奥胶囊用药不合理率均低于对照组,差异有统计学意义(P<0.05)。结论 基于AHM结合加权TOPSIS法的替吉奥胶囊用药合理性评价标准的科学性和可行性较高,运用该合理性评价标准进行用药合理性评价,并予以针对性干预,能够提高替吉奥胶囊的用药合理性。
AlMTo establish a rational drug use evaluation standard for tegafur-gimeracil-oteracil potassium capsules based on the attribute hierarchy method(AHM)combined with the weighted technique for order preference by similarity to an ideal solution(TOPSIS),rooted in drug utilization evaluation(DUE),subsequently evaluating medication rationality of tegafur-gimeracil-oteracil potassium capsules in clinical settings.METHODS Rational use criteria for tegafur-gimeracil-oteracil potassium capsules were established based on prescribing information,clinical guidelines,and peer-reviewed literature in January 2023.A total of 120 cases using tegafur-gimeracil-oteracil potassium capsules from January to December 2022(pre-intervention)were randomly selected to be included in the control group,and 120 cases from January to December 2023(post-intervention)were included in the study group.An analysis was conducted to identify the reasons for the improper use of tegafur-gimeracil-oteracil potassium capsules within the control group,and targeted improvement measures were proposed based on the established evaluation criteria for the rational use of tegafur-gimeracil-oteracil potassium capsules.The x test was used to compare the rationality rate use of tegafur-gimeracil-oteracil potassium capsules between groups.RESULTS In the control group of 120 cases,the highest C,value was 100%and the lowest was 36.6%.There were 47 cases(39.17%)with C,≥80%,40 cases(33.33%)with 60%≤C,<80%,and 33 cases(27.50%)with C,<60%.In the study group of 120 cases,the highest C,value was 100%and the lowest was 43.6%.There were 81 cases(67.50%)with C,≥80%,16 cases(13.33%)with 60%≤C,<80%,and 23 cases(19.17%)with C,<60%.Compared with the control group,the proportion of cases with C,≥80%increased significantly in the study group(P<0.05).The irrational drug use rate of the study group was lower than that of the control group in terms of usage and dosage,indications,course of treatment,adverse reaction monitoring and treatment,with a significant statistical difference(P<0.05).CONCLUSION The evaluation system of drug use reasonableness of tegafur-gimeracil-oteracil potassium capsules constructed by the AHM combined with the weighted TOPSIS method is reasonable and feasible.Implementing criterion-based system enables objective clinical assessments and targeted pharmaceutical interventions,thereby optimizing medication rationality.
作者
魏曼玉
梁英丽
WEI Manyu;LIANG Yingli(Department of Pharmacy,Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui Universityof ChineseMedicine,Fuyang236600,China)
出处
《中国临床药学杂志》
2025年第7期503-508,共6页
Chinese Journal of Clinical Pharmacy
关键词
属性层次模型
优劣解距离法
替吉奥胶囊
用药合理性评价
attribute hierarchy method
TOPSIS method
tegafur-gimeracil-oteracil potassium capsule
medication rationalityevaluation
